{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-020366","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.427340+00:00","generated_at":"2026-05-25T09:47:52.838580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Q4 net loss $12.8M, cash $170M; ADVANCED-2 12-month data by mid-2025","bullets":["Cash and equivalents $170.3M as of Dec 31, 2024, funded into 2027 after $100M public offering.","Full year 2024 net loss $44.6M ($2.17/share) vs $40.4M ($3.57/share) in 2023.","ADVANCED-2 trial: 12-month data from evaluable NMIBC patients expected by mid-2025; 72% CR at 6 months reported.","THRIVE-3 registrational trial of IV Choline Chloride to start in 1H 2025; FDA Fast Track granted.","STARBORN-1 interim update for TARA-002 in pediatric LMs expected by end of 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-020366","json":"https://secwatch.observer/filing/0001213900-25-020366.json","markdown":"https://secwatch.observer/filing/0001213900-25-020366.md","text":"https://secwatch.observer/filing/0001213900-25-020366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/0001213900-25-020366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea0232641-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T09:47:52.838580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}